Granules India Q1 net surges 60% to ₹180 cr on higher revenue
Granules India reported a 60% increase in net profit for the first quarter of FY2027, driven by strong performance in complex generics and international markets. Despite the profit surge, the company noted ongoing challenges regarding supply chain volatility.
Why it matters
The company's financial performance reflects broader trends in the pharmaceutical manufacturing sector and global supply chain management.
Generic drugmaker Granules India reported 60% year-on-year (YoY) surge in net profit to ₹179.96 crore on higher revenues from operations. in the first quarter (Q1) of FY2027.
Growth in the contribution of complex generics and from Europe and rest of world markets boosted the revenue by 22% YoY to ₹1,476.8 crore, even as share of North American market dipped to 72% against 77% in Q1FY26.
Complex generic products share in finished dosages (FD) moved up YoY from 39% to 50%, lifting gross margin to 65.6% and earnings before interest, depreciation, taxes and amortisation (Ebitda) margin to 22.9%, the company said.
FD, active pharmaceuticals ingredients (API), pharmaceutical formulation intermediates (PFI) and peptides CDMO contributed 74%, 13%, 9% and 4% of revenue from operations respectively.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in